Zoetis ($ZTS) Companion Animal Product Growth and Competition Case
$ZTS investors filed a claim against Zoetis for allegedly overstating veterinarian demand, market share strength, and growth prospects for key pet care products while downplaying safety concerns and rising competition.
After Zoetis disclosed worsening competition, weaker prescription demand, and declining Companion Animal sales trends, $ZTS fell 21.5% on May 7, 2026.
$ZTS investors can join this case to be notified about potential recovery.
Case Details:
Between January 14, 2025 and May 6, 2026, Zoetis told investors its Companion Animal business remained a durable growth engine supported by strong veterinarian adoption, growing market share, and loyal customers. Executives emphasized continued momentum for Librela, Apoquel, Cytopoint, and Simparica Trio, while assuring investors the company was successfully handling new competition and maintaining leadership across key pet care markets.
However, during this period, investors allege Zoetis was experiencing weakening demand and growing competitive pressure across several flagship products. Zoetis allegedly failed to disclose that veterinarians were becoming more cautious in prescribing Librela following FDA safety warnings tied to serious neurological events in dogs, that Simparica Trio was losing market share to lower-priced competing products with broader coverage, and that Apoquel and Cytopoint were facing mounting competition that was eroding growth and prescription trends.
Then, on August 5, 2025, Zoetis reported weakening demand trends within its Companion Animal portfolio despite raising full-year guidance. $ZTS fell 3.8%, closing at $146.12.
Additional revelations followed on May 7, 2026, including disclosures that competition had intensified across dermatology and parasiticides, pet owners had become more price sensitive, and new competitors were not expanding the overall market.
By May 7, 2026, shares had dropped to $87.31, representing a total decline of 40.3% from the August 2025 disclosure price.
Based on these events, $ZTS investors filed a claim against Zoetis, alleging the company:
It overstated the strength of demand for its flagship pet care products.
It failed to warn investors that safety concerns and lower-priced competitors were weakening veterinarian adoption and market share.
It inflated expectations for long-term growth across its Companion Animal business.
Investors argue Zoetis misled the market about the durability of its Companion Animal product portfolio, causing losses when worsening sales and competitive pressures emerged.